Abeona Therapeutics Inc. (ABEO)
NasdaqCM
Price as at 30 Sept 2026, 15:56 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Abeona Therapeutics Inc. trades at $5.27. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$2.23M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$1.60M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$1.31M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$1.20M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$499.0K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own ABEO?
7 of the institutions we track reported a position in ABEO in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ABEO data?
Fundamentals for ABEO come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 15:56 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ABEO, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.